Identification of alternative splicing markers for breast cancer

Cancer Research

Volumn 68, Issue 22, 2008, Pages 9525-9531

  Venables, Julian P ^a   Klinck, Roscoe ^a   Bramard, Anne ^a   Inkel, Lyna ^a   Dufresne Martin, Geneviève ^a   Koh, ChuShin ^a   Gervais Bird, Julien ^a   Lapointe, Elvy ^a   Froehlich, Ulrike ^a   Durand, Mathieu ^a   Gendron, Daniel ^a   Brosseau, Jean Philippe ^a   Thibault, Philippe ^a   Lucier, Jean Francois ^a   Tremblay, Karine ^a   Prinos, Panagiotis ^a   Wellinger, Raymund J ^b   Chabot, Benoit ^b   Rancourt, Claudine ^b   Elela, Sherif Abou ^b  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA;

ADULT; AGED; ALTERNATIVE RNA SPLICING; ARTICLE; BREAST CANCER; CANCER GRADING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HIGH THROUGHPUT SCREENING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN DOMAIN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GENE; VALIDATION PROCESS;

EID: 56449105613     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-1769     Document Type: Article

References (55)

1. Cheang MC, van de Rijn M, Nielsen TO. Gene expression profiling of breast cancer. Annu Rev Pathol 2007;3:67-97.
2. Pajares MJ, Ezponda T, Catena R, Calvo A, Pio R, Montuenga LM. Alternative splicing: an emerging topic in molecular and clinical oncology. Lancet Oncol 2007;8: 349-57.
3. Blencowe BJ. Alternative splicing: new insights from global analyses. Cell 2006;126:37-47.
4. Moore MJ, Silver PA. Global analysis of mRNA splicing. RNA 2008;14:197-203.
5. Venables JP. Aberrant and alternative splicing in cancer. Cancer Res 2004;64:7647-54.
6. Borsi L, Carnemolla B, Nicolo G, Spina B, Tanara G, Zardi L. Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int J Cancer 1992;52:688-92.
7. Huang CS, Shen CY, Wang HW, Wu PE, Cheng CW. Increased expression of SRp40 affecting CD44 splicing is associated with the clinical outcome of lymph node metastasis in human breast cancer. Clin Chim Acta 2007;384:69-74.
8. Skotheim RI, Nees M. Alternative splicing in cancer: noise, functional, or systematic? Int J Biochem Cell Biol 2007;39:1432-49.
9. Watermann DO, Tang Y, Zur Hausen A, Jager M, Stamm S, Stickeler E. Splicing factor Tra2-1 is specifically induced in breast cancer and regulates alternative splicing of the CD44 gene. Cancer Res 2006; 66:4774-80.
10. Li C, Kato M, Shiue L, Shively JE, Ares M, Jr., Lin RJ. Cell type and culture condition-dependent alternative splicing in human breast cancer cells revealed by splicing-sensitive microarrays. Cancer Res 2006;66: 1990-9.
11. Klinck R, Bramard A, Inkel L, et al. Multiple alternative splicing markers for ovarian cancer. Cancer Res 2008;68:657-63.
12. Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J. qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol 2007;8:R19.
13. Thierry-Mieg D, Thierry-Mieg J. AceView: a comprehensive cDNA-supported gene and transcripts annotation. Genome Biol 2006;7 Suppl 1:S12 1-4.
14. Pan Q, Shai O, Misquitta C, et al. Revealing global regulatory features of mammalian alternative splicing using a quantitative microarray platform. Mol Cell 2004; 16:929-41.
15. Fisher ER, Osborne CK, McGuire WL, et al. Correlation of primary breast cancer histopathology and estrogen receptor content. Breast Cancer Res Treat 1981;1:37-41.
16. Belfiore A. The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des 2007;13:671-86.
17. Venables JP. Unbalanced alternative splicing and its significance in cancer. Bioessays 2006;28:378-86.
18. Xu Q, Lee C. Discovery of novel splice forms and functional analysis of cancer-specific alternative splicing in human expressed sequences. Nucleic Acids Res 2003; 31:5635-43.
19. Bae J, Leo CP, Hsu SY, Hsueh AJ. MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain. J Biol Chem 2000;275:25255-61.
20. Soejima K, Fang W, Rollins BJ. DNA methyltransferase 3b contributes to oncogenic transformation induced by SV40T antigen and activated Ras. Oncogene 2003;22: 4723-33.
21. Beaulieu N, Morin S, Chute IC, Robert MF, Nguyen H, MacLeod AR. An essential role for DNA methyltransferase DNMT3B in cancer cell survival. J Biol Chem 2002; 277:28176-81.
22. Veeramani S, Igawa T, Yuan TC, et al. Expression of p66(Shc) protein correlates with proliferation of human prostate cancer cells. Oncogene 2005;24:7203-12.
23. Yoshizawa-Sugata N, Ishii A, Taniyama C, Matsui E, Arai K, Masai H. A second human Dbf4/ASK-related protein, Drf1/ASKL1, is required for efficient progression of S and M phases. J Biol Chem 2005;280:13062-70.
24. Saito S, Kitayama J, Jin ZX, et al. β-chemokine, macrophage inflammatory protein-1β (MIP-1β), is highly expressed in diffuse type human gastric cancers. J Exp Clin Cancer Res 2003;22:453-9.
25. Baxendale AJ, Dawson CW, Stewart SE, et al. Constitutive activation of the CD40 pathway promotes cell transformation and neoplastic growth. Oncogene 2005;24:7913-23.
26. Nitori N, Ino Y, Nakanishi Y, et al. Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma. Clin Cancer Res 2005;11:2531-9.
27. Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat Med 2003;9:458-62.
28. Liau SS, Jazag A, Whang EE. HMGA1 is a determinant of cellular invasiveness and in vivo metastatic potential in pancreatic adenocarcinoma. Cancer Res 2006;66: 11613-22.
29. Hunter DJ, Kraft P, Jacobs KB, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007;39:870-4.
30. White ES, Baralle FE, Muro AF. New insights into form and function of fibronectin splice variants. J Pathol 2008;216:1-14.
31. Oshiro MM, Kim CJ, Wozniak RJ, et al. Epigenetic silencing of DSC3 is a common event in human breast cancer. Breast Cancer Res 2005;7:R669-80.
32. Suzuki K, Takahashi K. Regulation of lamellipodia formation and cell invasion by CLIP-170 in invasive human breast cancer cells. Biochem Biophys Res Commun 2008;368:199-204.
33. Maxwell CA, Rasmussen E, Zhan F, et al. RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma. Blood 2004;104:1151-8.
34. Alves F, Vogel W, Mossie K, Millauer B, Hofler H, Ullrich A. Distinct structural characteristics of discoidin I subfamily receptor tyrosine kinases and complementary expression in human cancer. Oncogene 1995;10: 609-18.
35. Debily MA, Camarca A, Ciullo M, et al. Expression and molecular characterization of alternative transcripts of the ARHGEF5/TIM oncogene specific for human breast cancer. Hum Mol Genet 2004;13:323-34.
36. Radisky DC, Levy DD, Littlepage LE, et al. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 2005;436:123-7.
37. Datta D, Flaxenburg JA, Laxmanan S, et al. Rasinduced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer. Cancer Res 2006;66:9509-18.
38. Hisatomi H, Kohno N, Wakita K, et al. Novel alternatively spliced variant with a deletion of 52 BP in exon 6 of the progesterone receptor gene is observed frequently in breast cancer tissues. Int J Cancer 2003; 105:182-5.
39. Wang L, Duke L, Zhang PS, et al. Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer. Cancer Res 2003;63:4724-30.
40. Kaczmarek J, Castellani P, Nicolo G, Spina B, Allemanni G, Zardi L. Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int J Cancer 1994;59:11-6.
41. Luqmani YA, Mortimer C, Yiangou C, et al. Expression of 2 variant forms of fibroblast growth factor receptor 1 in human breast. Int J Cancer 1995; 64:274-9.
42. Poola I, Speirs V. Expression of alternatively spliced estrogen receptor α mRNAs is increased in breast cancer tissues. J Steroid Biochem Mol Biol 2001;78: 459-69.
43. Erenburg I, Schachter B, Mira y Lopez R, Ossowski L. Loss of an estrogen receptor isoform (ER α δ 3) in breast cancer and the consequences of its reexpression: interference with estrogen-stimulated properties of malignant transformation. Mol Endocrinol 1997;11: 2004-15.
44. Sciacca L, Costantino A, Pandini G, et al. Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism. Oncogene 1999;18:2471-9.
45. Sciacca L, Mineo R, Pandini G, Murabito A, Vigneri R, Belfiore A. In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A. Oncogene 2002;21:8240-50.
46. Martensen PM, Oka K, Christensen L, et al. Breast carcinoma epithelial cells express a very low-density lipoprotein receptor variant lacking the O-linked glycosylation domain encoded by exon 16, but with full binding activity for serine proteinase/serpin complexes and Mr-40,000 receptor-associated protein. Eur J Biochem 1997;248:583-91.
47. Sabbioni S, Barbanti-Brodano G, Croce CM, Negrini M. GOK: a gene at 11p15 involved in rhabdomyosarcoma and rhabdoid tumor development. Cancer Res 1997; 57:4493-7.
48. Taylor CW. Store-operated Ca2+ entry: A STIMulating stOrai. Trends Biochem Sci 2006;31:597-601.
49. Dunbar AJ, Goddard C. Structure-function and biological role of βcellulin. Int J Biochem Cell Biol 2000;32:805-15.
50. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
51. Larder R, Chang L, Clinton M, Brown P. Gonadotropin-releasing hormone regulates expression of the DNA damage repair gene, Fanconi anemia A, in pituitary gonadotroph cells. Biol Reprod 2004;71: 828-36.
52. Fanti P, Nazareth M, Bucelli R, et al. Estrogen decreases chemokine levels in murine mammary tissue: implications for the regulatory role of MIP-1 α and MCP-1/JE in mammary tumor formation. Endocrine 2003;22:161-8.
53. Gauduchon J, Gouilleux F, Maillard S, Marsaud V, Renoir JM, Sola B. 4-Hydroxytamoxifen inhibits proliferation of multiple myeloma cells in vitro through down-regulation of c-Myc, up-regulation of p27Kip1, and modulation of Bcl-2 family members. Clin Cancer Res 2005;11:2345-54.
54. Auboeuf D, Batsche E, Dutertre M, Muchardt C, O'Malley BW. Coregulators: transducing signal from transcription to alternative splicing. Trends Endocrinol Metab 2007;18:122-9.
55. Hayes GM, Carrigan PE, Miller LJ. Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreatic carcinomas. Cancer Res 2007;67:2072-80.